See the DrugPatentWatch profile for Skytrofa
What is Skytrofa?
Skytrofa is a brand name for somapacitan, a once-weekly growth hormone (GH) therapy developed for the treatment of growth failure in children who need GH. It is designed to replace or provide GH as part of standard care for eligible pediatric patients.[1]
What conditions is Skytrofa used for?
Skytrofa is used to treat growth failure in children due to a need for growth hormone therapy.[1]
How is Skytrofa taken?
Skytrofa is administered as a once-weekly injection, reflecting its long-acting design compared with older daily GH regimens.[1]
How does Skytrofa compare with older growth hormone options?
Skytrofa’s main practical difference is the dosing frequency. Traditional GH therapies are often given daily, while Skytrofa is designed for once-weekly dosing, which can reduce the number of injections required.[1]
Who makes Skytrofa?
The product is associated with Novo Nordisk.[1]
What should patients and caregivers ask a clinician?
Because Skytrofa is an injectable growth hormone medicine, families typically ask about:
- Whether the child meets criteria for pediatric GH treatment
- The expected growth response and monitoring schedule
- Injection training and how to manage missed doses
- Safety monitoring while on long-acting GH therapy
Sources
[1] https://www.novonordisk-us.com/products/skytrofa.html